Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670959 | 0.97 | KDM4E (0.52) | KDM4EMEN1CYP1A2CYP2D6MAPT | |
| SCHEMBL6669032 | 0.88 | KDM4E (0.50) | KDM4EMEN1CYP1A2CYP2D6MAPT | |
| SCHEMBL6674713 | 0.87 | ALDH1A1 (0.46) | KDM4EMEN1CYP1A2CYP2D6MAPT | |
| SCHEMBL6673846 | 0.85 | KDM4E (0.50) | KDM4EMEN1CYP1A2CYP2D6MAPT | |
| SCHEMBL6674648 | 0.85 | KMT2A (0.41) | MEN1MAPTKMT2AHPGDALDH1A1 | |
| SCHEMBL6670165 | 0.84 | ALDH1A1 (0.46) | MEN1KMT2AHPGDPOLBGAA | |
| SCHEMBL6669855 | 0.84 | KDM4E (0.49) | KDM4EMEN1CYP1A2CYP2D6MAPT | |
| SCHEMBL6670907 | 0.83 | HSD11B1 (0.39) | MEN1KMT2AHPGDCNR2HSD11B1 | |
| SCHEMBL6672033 | 0.82 | KMT2A (0.41) | MEN1CYP1A2CYP2C19KMT2AHPGD | |
| SCHEMBL6670611 | 0.82 | HSD11B1 (0.40) | MEN1MAPTKMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0713702-B1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-09-29 | — | — | EP | claimed |
| US-6303623-B1 | TREATING ANXIETY IN A PATIENT IN NEED OF SUCH TREATMENT, COMPRISING ADMINISTERING BICYCLOLACTAM COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-10-16 | — | — | US | claimed |
| EP-0713702-A1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1996-05-29 | — | — | EP | claimed |
| EP-0713702-B1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6500819-B2 | HAS AN EXCELLENT ANXIOLYTIC EFFECT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICAL COMPANY LIMITED | 2002-07-25 | — | — | US | disclosed |
| US-6355668-B1 | ANXIOLYTIC AGENTS; SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6303623-B1 | TREATING ANXIETY IN A PATIENT IN NEED OF SUCH TREATMENT, COMPRISING ADMINISTERING BICYCLOLACTAM COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6159987-A | Bicyclolactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICALS, CO. (JP) | 2000-12-12 | — | — | US | disclosed |
| US-6004975-A | ANXIOLYTIC AGENTS WITH SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0713702-A1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1996-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | CYP11B1, GABRA6, CYP11B2 | KDM4E 2621/4885MEN1 3932/4885CYP1A2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.